Portfolio | Tmunity在A轮融资中增筹3500万美元

2018年4月19日，位于美国宾夕法尼亚州费城的 Tmunity Therapeutics公司宣布在A轮融资中又增筹3500万美元。Tmunity是一家处于临床阶段的未上市生物医药企业，专注于通过实现下一代T细胞免疫疗法的全部潜力来挽救生命和改善生活。这次追加的3500万美元来自Kleiner Perkins风险投资集团，使A轮总融资达到1.35亿美元。 Tmunity拥有多样化的管线组合，开发的新型治疗方式在控制体内T细胞激活和命运方面达到best-in-class效果。

Kleiner Perkins加入现有的Tmunity投资者包括平安风险投资公司，Parker癌症免疫治疗研究所，吉列德公司 (Gilead)，Be The Match BioTherapies，宾夕法尼亚大学和礼来亚洲基金。

“我们欢迎Kleiner Perkins加入我们已有的显赫的投资者团队。他们分享我们的愿景，即为患者提供新型细胞和基因治疗方法以及下一代个性化治疗，” Tmunity的总裁兼首席执行官Usman “Oz” Azam医学博士说。“我们为这次重大融资而感到自豪，并对我们公司的未来充满信心和激情。”

“Tmunity专注于T细胞治疗（CAR-T和TCR），这是癌症治疗中最有前途和令人兴奋的技术之一，”Kleiner Perkins的合伙人Beth Seidenberg博士表示。“该领域已通过被批准的B细胞恶性肿瘤治疗得到验证。现在的目标是将该技术和治疗应用于治疗实体瘤，如前列腺癌，胰腺癌，卵巢癌等其它最难治愈的癌症。”

正如之前宣布的，A轮融资将用于推进和扩大Tmunity的业务和运营结构，以支持新型T细胞免疫疗法组合的快速落地，开发和生产。这一平台将首先应用在治疗癌症上。

Tmunity建立在与宾夕法尼亚大学的独家合作和许可协议基础之上。公司的科学创始团队由Carl H. June医学博士领导，在细胞和基因治疗方面具有独家专有技术、无与伦比的专业知识，和首次临床应用的成功经验。今天，Tmunity的独特定位是整合最好的技术，并同时采用多种方法并行设计T细胞疗法，以便迅速推进到临床应用，优化和规模化生产，积极争取监管部门批准，从而有效地给患者以最先进的治疗手段。

关于KleinerPerkins

KleinerPerkins与最聪明的企业家合作，将颠覆性创意变成改变世界的企业。通过20个风险投资基金和四个发展基金募集了100亿美元，该公司已经投资了850多家公司，其中包括Google，App Dynamics，亚马逊，Flexus Biosciences，Nest，Waze，Twitter，JD.com和Square等先锋公司。Kleiner Perkins为企业家们提供多年的运营经验，将他们置于一个有影响力的网络中心，并加速他们的公司成长、成功，并改变世界。欲了解更多信息，请访问http://www.kpcb.com并关注我们@kpcb。

关于Tmunity Therapeutics

Tmunity是一家处于临床阶段的未上市生物医药企业，专注挖掘下一代T细胞免疫疗法的全部潜力，致力于帮助受恶劣疾病困扰的患者，挽救他们的生命，改善他们的生活。与宾夕法尼亚大学（Penn）的基础合作, 其创始团队（Carl  June，MD，Bruce Blazar，MD，Bruce Levine，PhD，Yangbing Zhao，MD，PhD ，Jim Riley, PhD和Anne Chew, PhD）的优秀履历、和在突破性科研，临床和生产方面上的资深专业造诣，使Tmunity成为T细胞医疗产业化的一个新的中心。该公司正在开发多样化的新型治疗组合，在控制体内T细胞激活和命运方面达到best-in-class效果。公司的最初重点是癌症，目前有两个项目在临床阶段。 Tmunity总部位于费城，利用Penn的实验室和生产设施及其位于Norristown, PA的专用cGMP生产厂房，致力于工艺改进和生产规模化，以支持其T细胞疗法的临床开发。欲了解更多信息，请访问www.tmunity.com。

附英文新闻：

Tmunity Raises Additional $35 Millionin Series A Financing,

Bringing Series A Total to $135 Million To Advance Next-Generation T Cell Therapies

PHILADELPHIA, PA, April 19, 2018 – Tmunity Therapeutics, Inc., a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy, today announced an additional $35 million Series A investment from Kleiner Perkins and affiliates. This investment brings the total Tmunity Series A financing to $135 million. Tmunity is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body.

Kleiner Perkins and affilates join existing Tmunity investors Ping An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences, Inc., Be The Match BioTherapies, University of Pennsylvania and Lilly Asia Ventures.

“We welcome Kleiner Perkins and affilates to an impressive list of committed investors who share in our vision to provide novel cell and gene therapy approaches and next-generation personalized treatments for patients,” said Usman “Oz” Azam, MD, President and Chief Executive Officer of Tmunity. “We are proud of this significant financial raise and enthuastic about the prospects ahead for our company.”

“Tmunity is focused on T cell therapy (CAR-T and TCR), one of the most promising and exciting technologies to emerge in the treatment of cancer,” said Beth Seidenberg, MD, general partner at Kleiner Perkins. “The field has been validated with approved therapies for B cell malignancies and the goal is to apply the technology and therapy to the treatment of solid tumors such as prostate, pancreatic, ovarian and other cancers that remain some of the toughest to cure.”

As previously announced, the proceeds from the Series A will be used to advance and expand the business and operational structure of Tmunity to support the rapid translation, development and manufacture of its portfolio of novel T cell based immunotherapies, first for the treatment of cancer.

Tmunity was founded on an exclusive collaboration and license agreement with the University of Pennsylvania, offering proprietary technologies and unparalleled expertise in first-in-patient cell and gene therapies of its scientific founders, led by Carl H. June, MD. Today, Tmunity is uniquely positioned to integrate the best technologies and pursue multiple approaches to engineered T celltherapies simultaneously in order to advance treatments into the clinic rapidly, optimize and scale manufacturing, pursue regulatory approvals aggressively, and thus deliver them effectively to patients.

About Kleiner Perkins
Kleiner Perkins partners with the brightest entrepreneurs to turn disruptive ideas into world-changing businesses. With $10 billion raised through 20 venture funds and four growth funds, the firm has invested in over 850 companies including pioneers such as Google, App Dynamics, Amazon, Flexus Biosciences, Nest, Waze, Twitter, JD.com and Square. Kleiner Perkins offers entrepreneurs years of operating experience, puts them at the center of an influential network, and accelerates their companies from success to significance. For more information, visit http://www.kpcb.com and follow us @kpcb.  

About Tmunity Therapeutics

Tmunity is a private clinical-stage biotherapeutics company focused on saving and improving lives by delivering the full potential of next-generation T cell immunotherapy to patients with devastating diseases.Integrating a foundational collaboration with the University of Pennsylvania (Penn) with the groundbreaking scientific, clinical and manufacturing expertise and demonstrated track record of its founders (Carl June, MD, Bruce Blazar, MD, Bruce Levine, PhD, Yangbing Zhao, MD, PhD, Jim Riley, PhD, and Anne Chew, PhD), Tmunity represents a new center of gravity in translational T cell medicine.The company is developing a diversified portfolio of novel treatments that exhibit best-in-class control over T cell activation and direction in the body, with an initial focus in cancer with two programs currently in the clinic. With headquarters in Philadelphia, Tmunity utilizes laboratories and production facilities at Penn and its own dedicated cGMP manufacturing facility in Norristown, PA, to pursue process improvement and production scale-up in support of clinical development of its T cell therapies. For more information, visit www.tmunity.com.

# # #

MediaContact:

Mike Beyer 

Sam Brown Inc. Healthcare Communications

312-961-2502

[e-mail]

近期文章：

欢迎关注：